January 26, 2018 | Blake Mossy
ConforMIS priced an underwritten public offering of 13.3 million shares of common stock, led by Cowen and Canaccord ; Suntrust Robingson Humphrey The company is pricing the stock at $1.50 per share before the underwriting discounts. The public offering is expected to raise $20 million in gross proceeds. Underwriters have the ability to purchase up to 2 million additional shares of common stock over a 30-day period.
Centric Medical received 510(k) clearance from the FDA for its Foot and Ankle Plating System, indicated for the stabilization and fixation of bone. The system is comprised of low-profile plates and self-drilling and self-tapping screws, designed to minimize soft tissue disruption and irritation. The plates are intended for metatarsal phalangeal fusions, lapidus fusions, midfoot fusions and calcaneal slide osteotomies.
PRODUCT INTRODUCTION & UPDATE
Bone Solutions reached a milestone of 50 implants of its OsteoCrete magnesium-based orthopedic medical device. The system is a bone void filler designed to assist with bone repair and generation. OsteoCrete is resorbable, capable of being assimilated back into the body, and is replaced with bone as the patient heals.
Spine Wave launched its GraftMag Delivery System, designed to simplify the bone graft delivery process. The system is comprised of two single use, 5cc graft magazine that are loaded with bone graft on the back table, while reducing funnel jams and requires one instrument pass into the graft site to complete the grafting procedure.
The Arthroscopy Association of North America (AANA) entered into a two-year collaboration agreement making VIrtaMed the preferred and exclusive partner for virtual reality simulation training. Under the terms of the agreement, AANA and VIrtaMed will work together to improve the training of arthroscopic surgery skills and standards for proficiency-based training curricula.
RTI Surgical announced the results from a peer-reviewed publication of two-year data of the SImmertry Sacroiliac Joint Fusion, assessing patient’s long-term fusion and pain reduction. The system is intended for the treatment of SI joint dysfunction. Researched viewed CTs for evidence of fusion at 12 months and 24 months after SI joint fusion with decortication and bone grafting using the system. The study indicated positive results with a 73 percent decrease in average pain and solid fusion across the SI joint.